New Zealand

Clavulox LC

Clavulox L.C. is specially prepared for the treatment of mastitis during lactation. It is bactericidal, with activity against clinically important bacteria commonly associated with bovine mastitis, including β–lactamase resistant bacteria.

Expand All
  • Clavulox L.C. is formulated for the treatment of mastitis in lactating cows. It has a notably broad spectrum of bactericidal activity against the bacteria commonly isolated from the bovine udder. Cases responding successfully to treatment include infections with the following major pathogens: Staphylococci spp. (including ß-lactamase producing strains); Streptococci spp. (including S. agalactiae, S. dysgalactiae and S. uberis); Escherichia coli (including ß-lactamase producing strains).

    Resistance to many antibiotics is caused by ß-lactamase enzymes that destroy the antibiotic before it can act on the bacteria. The clavulanate in the product counteracts this defence mechanism by inactivating the ß-lactamases, thus rendering the bacteria sensitive to the rapid bactericidal effect of amoxycillin at concentrations readily attainable in the udder. Prednisolone has an anti-inflammatory action that helps to reduce the potentially destructive swelling and inflammation associated with mastitis, without affecting the white cell response to infection.

    In-vitro, the product is active against a wide range of clinically important bacteria, including the following organisms that are commonly associated with bovine mastitis. Staphylococci spp. (including ß-lactamase producing strains), Streptococci spp. (including S. agalactiae, S. dysgalactiae and S. uberis), Actinomyces (Corynebacterium) (including A. pyogenes), Escherichia coli (including ß-lactamase producing strains). In addition, it is active in vitro against many of the less common udder pathogens, including: Bacillus cereus, Bacteroides (including ß-lactamase producing strains), Campylobacter spp. Klebsiellae and Pasteurellae. Clinically, the product has been shown to be an effective routine treatment for mastitis in lactating cows.

  • Efficacy – Multiple trials show high efficacy of Clavulox L.C. against the bacteria specified above. Bacteriological cure rates of 56% to 72%1 have been demonstrated. A New Zealand trial of spring mastitis showed bacteriological cure rates of 74%2.

    Broad spectrum – Clavulox L.C. is ideally suited for the first time treatment of clinical mastitis during calving and early lactation where the causative bacteria is unknown.

    Short milk withhold – Clavulox L.C. has the added advantage of a short milk withhold period of 48 hours (assume twice a day milking).

  • Clavulox L.C. is a pale, buff-coloured sterile oil suspension suitable for intramammary infusion.

    Clavulox L.C. is presented in packs of 24 syringes with each syringe containing 200mg amoxycillin (as amoxycillin trihydrate), 50mg clavulanic acid (as potassium clavulanate) and 10mg prednisolone in 3g of mineral oil base.

  • Administer a course of 3 syringes per infected quarter. The contents of one syringe is to be infused every 12 hours. After milking, clean and disinfect the teat before infusing the syringe contents.


    Meat: Cows producing meat or offal for human consumption must not be sold for slaughter either during treatment or within 3 days of the last treatment.

    Milk: Milk intended for sale for human consumption must be discarded during treatment for not less than 4 milkings or approximately 48 hours after the last treatment.

    Bobby Calves: Milk taken from cows during treatment and during the withholding period must not be fed to bobby calves.

    Store below 25°C (air conditioning).

  • Penicillins may cause hypersensitivity (allergy) following ingestion or skin contact. Do not handle this product if you know you are sensitised to, or if you have been advised not to work with, such preparations. Handle this product with great care to avoid exposure, taking all the recommended precautions, including the use of suitable protective clothing and gloves.

  • Zoetis Animal Health New Zealand Limited. Level 5, 8 Mahuhu Crescent, Auckland 1010, New Zealand. Tel: 0800 650 277, Fax: 0800 628 629. CLAVULOX is a registered trade mark of GlaxoSmithKline NZ Ltd. ACVM Registration No. A5945. RVM; Available only under Veterinary Authorisation.


    1. Zoetis Animal Health Trial Report Numbers 2134, 93/5375, 2544
    2. Zoetis Animal Health Trial (unpublished – R Beal 2000)
  • For technical enquiries please phone Zoetis Technical Services on 0800 650 277.